# Pomalidomide, Ixazomib Citrate, and Dexamethasone in Treating Patients With Previously Treated Multiple Myeloma or Plasma Cell Leukemia

> **NCT02547662** · PHASE2 · COMPLETED · sponsor: **Mayo Clinic** · enrollment: 17 (actual)

## Conditions studied

- Plasma Cell Leukemia
- Plasma Cell Myeloma
- Plasmacytoma

## Interventions

- **DRUG:** Dexamethasone
- **DRUG:** Ixazomib Citrate
- **OTHER:** Laboratory Biomarker Analysis
- **DRUG:** Pomalidomide

## Key facts

- **NCT ID:** NCT02547662
- **Lead sponsor:** Mayo Clinic
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2015-12-24
- **Primary completion:** 2020-10-30
- **Final completion:** 2020-10-30
- **Target enrollment:** 17 (ACTUAL)
- **Last updated:** 2023-10-30


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02547662

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02547662, "Pomalidomide, Ixazomib Citrate, and Dexamethasone in Treating Patients With Previously Treated Multiple Myeloma or Plasma Cell Leukemia". Retrieved via AI Analytics 2026-06-08 from https://api.ai-analytics.org/clinical/NCT02547662. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*